Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 28, Issue 14, 2015, Pages 1621-1632

  Adekola, Henry ^a,b   Romero, Roberto ^a,c,d   Chaemsaithong, Piya ^a,b   Korzeniewski, Steven J ^a,b,d   Dong, Zhong ^a,b   Yeo, Lami ^a,b   Hassan, Sonia S ^a,b   Chaiworapongsa, Tinnakorn ^a,b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Endothelial cell activation; endothelial dysfunction; fetal death; preterm labor; small for gestational age; soluble endoglin; soluble vascular endothelial growth factor receptor 1

Indexed keywords

DERMATAN SULFATE DERIVATIVE; ENDOCAN; ENDOGLIN; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; BIOLOGICAL MARKER; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN;

ACUTE PYELONEPHRITIS; ADULT; ARTICLE; BACTEREMIA; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CARBOHYDRATE BLOOD LEVEL; CELL ACTIVATION; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DISEASE SEVERITY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS DEATH; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PREECLAMPSIA; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; PROGNOSIS; SMALL FOR DATE INFANT; UPREGULATION; ACUTE DISEASE; BLOOD; CASE CONTROL STUDY; PRE-ECLAMPSIA; PREGNANCY; PYELONEPHRITIS; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; NEOPLASM PROTEINS; PRE-ECLAMPSIA; PREGNANCY; PROTEOGLYCANS; PYELONEPHRITIS; SEVERITY OF ILLNESS INDEX;

EID: 84941095013     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2014.964676     Document Type: Article

References (249)

1. Young J. The aetiology of eclampsia and albuminuria and their relation to accidental haemorrhage: an anatomical and experimental investigation. Proc R Soc Med 1914;7:307-48.
2. Page EW. On the pathogenesis of pre-eclampsia and eclampsia. J Obstet Gynaecol Br Commonw 1972;79:883-94.
3. Romero R, Lockwood C, Oyarzun E, et al. Toxemia: new concepts in an old disease. Semin Perinatol 1988;12:302-23.
4. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4.
5. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46:1243-9.
6. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
7. Lindheimer MD, Roberts JM, Cunningham GC, et al. Introduction, history, controversies and definitions. In: Lindheimer MD, Roberts JM, Cunningham GC, eds. Chesley's hypertensive disorders in pregnancy. San Diego: Elsevier;2009:1-24.
8. Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet 2010;376:631-44.
9. Chaiworapongsa T, Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014;10:466-80.
10. Sacks GP, Studena K, Sargent K, et al. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998;179:80-6.
11. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180:499-506.
12. Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001;185:792-7.
13. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta 2003;24:S21-7.
14. Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol 2004;24:565-70.
15. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013;208:287.e1-15.
16. Bouwland-Both MI, Steegers EA, Lindemans J, et al. Maternal soluble fms-like tyrosine kinase-1, placental growth factor, plasminogen activator inhibitor-2, and folate concentrations and early fetal size: the Generation R study. Am J Obstet Gynecol 2013;209:121.e1-11.
17. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
18. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J Hypertens 1991;4:700-8.
19. Friedman SA, Schiff E, Emeis JJ, et al. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 1995;172:202-3.
20. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996;1:107-16.
21. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5-15.
22. Taylor RN, de Groot CJ, Cho YK, et al. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:17-31.
23. Cindrova-Davies T. Gabor than award lecture 2008: pre-eclampsia - from placental oxidative stress to maternal endothelial dysfunction. Placenta 2009;30:S55-65.
24. Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol 2012;64:309-20.
25. Sandvik MK, Leirgul E, Nygard O, et al. Preeclampsia in healthy women and endothelial dysfunction 10 years later. Am J Obstet Gynecol 2013;209:569.e1-10.
26. Cunningham FG, Pritchard JA. Hematologic considerations of pregnancy-induced hypertension. Semin Perinatol 1978;2:29-38.
27. Weenink GH, Treffers PE, Vijn P, et al. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984;148:1092-7.
28. Romero R, Mazor M, Lockwood CJ, et al. Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension. Am J Perinatol 1989;6:32-8.
29. de Boer K, ten Cate JW, Sturk A, et al. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989;160:95-100.
30. Cadroy Y, Grandjean H, Pichon J, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993;100:416-20.
31. Chaiworapongsa T, Yoshimatsu J, Espinoza J, et al. Evidence of in vivo generation of thrombin in patients with smallfor-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002;11:362-7.
32. Dekker G. Prothrombotic mechanisms in preeclampsia. Thromb Res 2005;115:17-21.
33. Erez O, Romero R, Kim SS, et al. Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med 2008;21:345-55.
34. Erez O, Romero R, Hoppensteadt D, et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med 2008;21:855-69.
35. Kenny LC, Baker PN, Cunningham FG. Platelets, coagulation, and the liver. In: Lindheimer MD, Roberts JM, Cunningham GC, eds. Chesley's hypertensive disorders in pregnancy. San Diego: Elsevier;2009:335-51.
36. Socol ML, Weiner CP, Louis G, et al. Platelet activation in preeclampsia. Am J Obstet Gynecol 1985;151:494-7.
37. Csaicsich P, Deutinger J, Tatra G. Platelet specific proteins (beta-thromboglobulin and platelet factor 4) in normal pregnancy and in pregnancy complicated by preeclampsia. Arch Gynecol Obstet 1989;244:91-5.
38. Ahmed Y, van Iddekinge B, Paul C, et al. Retrospective analysis of platelet numbers and volumes in normal pregnancy and in preeclampsia. Br J Obstet Gynaecol 1993;100:216-20.
39. Major HD, Campbell RA, Silver RM, et al. Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia. Am J Obstet Gynecol 2014;210:547.e1-7.
40. Deng L, Bremme K, Hansson LO, et al. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994;84:941-5.
41. Molvarec A, Rigo Jr J, Boze T, et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009;101:305-11.
42. Stepanian A, Cohen-Moatti M, Sanglier T, et al. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol 2011;31:1703-9.
43. Xiong Y, Zhou SF, Zhou R, et al. Alternations of maternal and cord plasma hemostasis in preeclampsia before and after delivery. Hypertens Pregnancy 2011;30:347-58.
44. Aref S, Goda H. Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology 2013;18:237-41.
45. Stubbs TM, Lazarchick J, Horger III EO, Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. Am J Obstet Gynecol 1984;150:885-7.
46. Friedman SA, de Groot CJ, Taylor RN, et al. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1994;170:838-41.
47. Kupferminc MJ, Peaceman AM, Wigton TR, et al. Fetal fibronectin levels are elevated in maternal plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1995;172:649-53.
48. Gredmark T, Bergman B, Hellstrom L. Total fibronectin in maternal plasma as a predictor for preeclampsia. Gynecol Obstet Invest 1999;47:89-94.
49. Chavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, et al. Maternal plasma cellular fibronectin concentrations in normal and preeclamptic pregnancies: a longitudinal study for early prediction of preeclampsia. Am J Obstet Gynecol 2002;187:595-601.
50. Aydin T, Varol FG, Sayin NC. Third trimester maternal plasma total fibronectin levels in pregnancy-induced hypertension: results of a tertiary center. Clin Appl Thromb Hemost 2006;12:33-9.
51. Leeflang MM, Cnossen JS, van der Post JA, et al. Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2007;133:12-9.
52. Powers RW, Catov JM, Bodnar LM, et al. Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome. Reprod Sci 2008;15:374-81.
53. Dane C, Buyukasik H, Dane B, et al. Maternal plasma fibronectin and advanced oxidative protein products for the prediction of preeclampsia in high risk pregnancies: a prospective cohort study. Fetal Diagn Ther 2009;26:189-94.
54. Uzun H, Konukoglu D, Albayrak M, et al. Increased maternal serum and cord blood fibronectin concentrations in preeclampsia are associated with higher placental hyaluronic acid and hydroxyproline content. Hypertens Pregnancy 2010;29:153-62.
55. Bodova KB, Biringer K, Dokus K, et al. Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia. Dis Markers 2011;30:191-6.
56. Rasanen J, Quinn MJ, Laurie A, et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol 2014. [Epub ahead of print].
57. Austgulen R, Lien E, Vince G, et al. Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 1997;71:53-8.
58. Krauss T, Kuhn W, Lakoma C, et al. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obstet Gynecol 1997;177:443-9.
59. Heyl W, Handt S, Reister F, et al. The role of soluble adhesion molecules in evaluating endothelial cell activation in preeclampsia. Am J Obstet Gynecol 1999;180:68-72.
60. Chaiworapongsa T, Romero R, Yoshimatsu J, et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med 2002;12:19-27.
61. Coata G, Pennacchi L, Bini V, et al. Soluble adhesion molecules: marker of pre-eclampsia and intrauterine growth restriction. J Matern Fetal Neonatal Med 2002;12:28-34.
62. Kim SY, Ryu HM, Yang JH, et al. Maternal serum levels of VCAM-1, ICAM-1 and E-selectin in preeclampsia. J Korean Med Sci 2004;19:688-92.
63. Szarka A, Rigo Jr J, Lazar L, et al. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59.
64. Lewis DF, Canzoneri BJ, Gu Y, et al. Maternal levels of prostacyclin, thromboxane, ICAM, and VCAM in normal and preeclamptic pregnancies. Am J Reprod Immunol 2010;64:376-83.
65. Molvarec A, Szarka A, Walentin S, et al. Serum heat shock protein 70 levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in women with preeclampsia. Clin Chim Acta 2011;412:1957-62.
66. Fei X, Hongxiang Z, Qi C, et al. Maternal plasma levels of endothelial dysfunction mediators including AM, CGRP, sICAM-1 and tHcy in pre-eclampsia. Adv Clin Exp Med 2012;21:573-9.
67. Metz TD, Allshouse AA, Euser AG, et al. Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers. Am J Obstet Gynecol 2014. [Epub ahead of print].
68. Rappaport VJ, Hirata G, Yap HK, et al. Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 1990;162:138-46.
69. Yamamoto T, Takahashi Y, Kuno S, et al. Effects of anti-endothelial cell antibody in pre-eclampsia on endothelin-1 release from cultured endothelial cells. Immunol Cell Biol 1997;75:340-4.
70. Yamamoto T, Geshi Y, Kuno S, et al. Anti-endothelial cell antibody in preeclampsia: clinical findings and serum cytotoxicity to endothelial cell. Nihon Rinsho Meneki Gakkai Kaishi 1998;21:191-7.
71. Rubin DB, Wiener-Kronish JP, Murray JF, et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990;86:474-80.
72. Sudhoff T, Wehmeier A, Kliche KO, et al. Levels of circulating endothelial adhesion molecules (sE-selectin and sVCAM-1) in adult patients with acute leukemia. Leukemia 1996;10:682-6.
73. Kayal S, Jais JP, Aguini N, et al. Elevated circulating E-selectin, intercellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med 1998;157:776-84.
74. McGill SN, Ahmed NA, Christou NV. Increased plasma von Willebrand factor in the systemic inflammatory response syndrome is derived from generalized endothelial cell activation. Crit Care Med 1998;26:296-300.
75. Lyall F, Hayman RG, Ashworth JR, et al. Relationship of cell adhesion molecule expression to endothelium-dependent relaxation in normal pregnancy and pregnancies complicated with preeclampsia or fetal growth restriction. J Soc Gynecol Investig 1999;6:196-201.
76. Bruserud O, Ulvestad E. Expression and release of adhesion molecules by human acute myelogenous leukemia blasts. Leuk Res 1999;23:149-57.
77. Bretelle F, Sabatier F, Blann A, et al. Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: comparison with pre-eclampsia. BJOG 2001;108:1277-82.
78. Parra-Cordero M, Turan OM, Kaur A, et al. Maternal serum soluble adhesion molecule levels at 11 + 0-13 + 6 weeks and subsequent development of pre-eclampsia. J Matern Fetal Neonatal Med 2007;20:793-6.
79. Costa C, Touscoz GA, Bergallo M, et al. Non-organ-specific and anti-endothelial antibodies in relation to CMV infection and acute rejection in renal transplant recipients. Clin Transplant 2010;24:488-92.
80. Papakonstantinou K, Economou E, Hasiakos D, et al. Antepartum and postpartum maternal plasma levels of E-selectin in preeclampsia, gestational proteinuria and gestational hypertension. Eur J Obstet Gynecol Reprod Biol 2010;153:112-3.
81. Scherpereel A, Depontieu F, Grigoriu B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006;34:532-7.
82. De Freitas Caires N, Legendre B, Parmentier E, et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 2013;78-79:45-51.
83. Ozaki K, Toshikuni N, George J, et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer 2014;5:221-30.
84. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
85. Lenburg ME, Liou LS, Gerry NP, et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer 2003;3:31.
86. Borczuk AC, Shah L, Pearson GD, et al. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004;170:167-74.
87. Hatfield KJ, Lassalle P, Leiva RA, et al. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology 2011;16:351-6.
88. Favaro D, Santarosa M, Quaia M, et al. Interleukin-6 and soluble intercellular adhesion molecule-1 in renal cancer patients and cultured renal cancer cells. Urol Oncol 1997;3:51-8.
89. Hoffmann R, Franzke A, Buer J, et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 1999;79:1742-5.
90. Zhang WH, Qiao ZH, Fan XH, et al. The role of intercellular adhesion molecule-1 in binding of acute myeloid leukemic blasts cells to human umbilical vein endothelial cells. Zhonghua Nei Ke Za Zhi 2003;42:413-6.
91. Basoglu M, Atamanalp SS, Yildirgan MI, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res 2007;39:136-40.
92. Gogali A, Charalabopoulos K, Zampira I, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest 2010;138:1173-9.
93. Qian Q, Zhan P, Sun WK, et al. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma 2012;59:433-9.
94. Touvier M, Fezeu L, Ahluwalia N, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013;177:3-13.
95. Ishihara N, Matsuo H, Murakoshi H, et al. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002;186:158-66.
96. Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1997;177:1003-10.
97. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22:143-8.
98. Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996;87: 163-8.
99. Cunningham FG, Morris GB, Mickal A. Acute pyelonephritis of pregnancy: a clinical review. Obstet Gynecol 1973;42:112-7.
100. Gilstrap III LC, Cunningham FG, Whalley PJ. Acute pyelonephritis in pregnancy: an anterospective study. Obstet Gynecol 1981;57:409-13.
101. Ogge G, Romero R, Kusanovic JP, et al. Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med 2010;23:820-7.
102. Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25-40.
103. Chaiworapongsa T, Romero R, Kusanovic JP, et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol 2010;35:155-62.
104. Kurmanavicius J, Florio I, Wisser J, et al. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24-42 weeks of gestation. Ultrasound Obstet Gynecol 1997;10:112-20.
105. Vita JA, Keaney Jr JF, Endothelial function: a barometer for cardiovascular risk? Circulation 2002;106:640-2.
106. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115:1285-95.
107. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708-14.
108. Bauer V, Sotnikova R. Nitric oxide - the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys 2010;29:319-40.
109. Cacanyiova S. The vasoactive role of nitric oxide: physiological and morphological aspects. Curr Pharm Biotechnol 2011;12:1294-304.
110. Gkaliagkousi E, Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front Biosci (Landmark Ed) 2011;16:1873-97.
111. Vita JA. Endothelial function. Circulation 2011;124:e906-12.
112. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33:829-837, 837a-d.
113. Tousoulis D, Kampoli AM, Tentolouris C, et al. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012;10:4-18.
114. van Hinsbergh VW. Endothelium - role in regulation of coagulation and inflammation. Semin Immunopathol 2012;34:93-106.
115. Lei J, Vodovotz Y, Tzeng E, et al. Nitric oxide, a protective molecule in the cardiovascular system. Nitric Oxide 2013;35:175-85.
116. Loscalzo J. The identification of nitric oxide as endothelium-derived relaxing factor. Circ Res 2013;113:100-3.
117. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-31.
118. Corson MA, James NL, Latta SE, et al. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res 1996;79:984-91.
119. Ballermann BJ, Dardik A, Eng E, et al. Shear stress and the endothelium. Kidney Int Suppl 1998;67:S100-8.
120. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev 2009;89:481-534.
121. Boon RA, Horrevoets AJ. Key transcriptional regulators of the vasoprotective effects of shear stress. Hamostaseologie 2009;29:39-40, 41-33.
122. Vessieres E, Freidja ML, Loufrani L, et al. Flow (shear stress)-mediated remodeling of resistance arteries in diabetes. Vascul Pharmacol 2012;57:173-8.
123. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001;280:F193-206.
124. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med 2004;10:143-5.
125. Sessa WC. eNOS at a glance. J Cell Sci 2004;117:2427-9.
126. Igarashi J, Michel T. S1P and eNOS regulation. Biochim Biophys Acta 2008;1781:489-95.
127. Rafikov R, Fonseca FV, Kumar S, et al. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 2011;210:271-84.
128. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008;10:1713-65.
129. Rizzo V, McIntosh DP, Oh P, et al. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J Biol Chem 1998;273:34724-9.
130. Garcia-Cardena G, Comander J, Anderson KR, et al. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001;98:4478-85.
131. Koo A, Nordsletten D, Umeton R, et al. In silico modeling of shear-stress-induced nitric oxide production in endothelial cells through systems biology. Biophys J 2013;104:2295-306.
132. Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-23.
133. Bevilacqua MP, Pober JS, Wheeler ME, et al. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985;76:2003-11.
134. Yong K, Khwaja A. Leucocyte cellular adhesion molecules. Blood Rev 1990;4:211-25.
135. Bevilacqua MP, Pober JS, Mendrick DL, et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238-42.
136. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8:504-12.
137. Jutila MA. Leukocyte traffic to sites of inflammation. APMIS 1992;100:191-201.
138. Williams TJ, Hellewell PG. Endothelial cell biology. Adhesion molecules involved in the microvascular inflammatory response. Am Rev Respir Dis 1992;146:S45-50.
139. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
140. Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest 2013;123:540-1.
141. Grumbach IM, Chen W, Mertens SA, et al. A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 2005;39:595-603.
142. Lazzerini G, Del Turco S, Basta G, et al. Prominent role of NF-kappaB in the induction of endothelial activation by endogenous nitric oxide inhibition. Nitric Oxide 2009;21:184-91.
143. Lee KS, Kim J, Kwak SN, et al. Functional role of NF-kappaB in expression of human endothelial nitric oxide synthase. Biochem Biophys Res Commun 2014;448:101-7.
144. Panza JA, Quyyumi AA, Brush Jr. JE, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
145. Liao JK, Shin WS, Lee WY, et al. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-24.
146. Amato M, Frigerio B, Castelnuovo S, et al. Effects of smoking regular or light cigarettes on brachial artery flow-mediated dilation. Atherosclerosis 2013;228:153-60.
147. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014;34:509-15.
148. Talib J, Kwan J, Suryo Rahmanto A, et al. The smokingassociated oxidant hypothiocyanous acid induces endothelial nitric oxide synthase dysfunction. Biochem J 2014;457:89-97.
149. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6.
150. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-51.
151. Rochette L, Lorin J, Zeller M, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther 2013;140:239-57.
152. Magenta A, Greco S, Capogrossi MC, et al. Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction. Biomed Res Int 2014;2014:193095.
153. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12:383-9.
154. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci 2001;947:167-79; discussion 179-80.
155. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
156. Libby P, Aikawa M, Jain MK. Vascular endothelium and atherosclerosis. Handb Exp Pharmacol 2006;176:285-306.
157. Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol 2001;185:1118-23.
158. Lyall F, Greer IA, Boswell F, et al. Expression of cell adhesion molecules in placentae from pregnancies complicated by preeclampsia and intrauterine growth retardation. Placenta 1995;16:579-87.
159. Smith CW. Potential significance of circulating E-selectin. Circulation 1997;95:1986-8.
160. Vadachkoria S, Sanchez SE, Qiu C, et al. Hyperhomocyst(e)inemia and elevated soluble vascular cell adhesion molecule-1 concentrations are associated with an increased risk of preeclampsia. Gynecol Obstet Invest 2004;58:133-9.
161. Vadachkoria S, Woelk GB, Mahomed K, et al. Elevated soluble vascular cell adhesion molecule-1, elevated Homocyst(e)inemia, and hypertriglyceridemia in relation to preeclampsia risk. Am J Hypertens 2006;19:235-42.
162. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001;107:1209-10.
163. Daniel Y, Kupferminc MJ, Baram A, et al. A selective increase in plasma soluble vascular cell adhesion molecule-1 levels in preeclampsia. Am J Reprod Immunol 1999;41:407-12.
164. Baviera G, D'Anna R, Corrado F, et al. ICAM-1 in maternal serum and amniotic fluid as an early marker of preeclampsia and IUGR. J Reprod Med 2002;47:191-3.
165. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-64.
166. Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem 2012;87:172-8.
167. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417-25.
168. Bechard D, Scherpereel A, Hammad H, et al. Human endothelialcell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099-106.
169. Lee W, Ku SK, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014;229:620-30.
170. De Freitas Caires N, Barrier M, Sarrazin S, et al. Identification of cathepsin G in the generation of elastase-resistant fragment of the vascular endocan. Involvement in the regulation of LFA-1-dependent cascade. Crit Care 2010;13:P16.
171. Tissier S, Lancel S, Marechal X, et al. Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats. Shock 2004;21:352-7.
172. Bechard D, Gentina T, Delehedde M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001;276:48341-9.
173. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
174. Shin JW, Huggenberger R, Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 2008;112:2318-26.
175. Scherpereel A, Gentina T, Grigoriu B, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003;63:6084-9.
176. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
177. Ogge G, Romero R, Chaiworapongsa T, et al. Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. J Matern Fetal Neonatal Med 2010;23:476-87.
178. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today 1999;20:114-8.
179. Schiff E, Friedman SA, Baumann P, et al. Tumor necrosis factoralpha in pregnancies associated with preeclampsia or small-for-gestational-age newborns. Am J Obstet Gynecol 1994;170:1224-9.
180. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-9.
181. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998;40:102-11.
182. Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004;44:708-14.
183. Jonsson Y, Ruber M, Matthiesen L, et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006;70:83-91.
184. Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol 2007;58:21-30.
185. Borekci B, Aksoy H, Al RA, et al. Maternal serum interleukin-10, interleukin-2 and interleukin-6 in pre-eclampsia and eclampsia. Am J Reprod Immunol 2007;58:56-64.
186. Gu Y, Lewis DF, Deere K, et al. Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in women with preeclampsia. J Immunol 2008;181:4418-22.
187. Sibai B, Romero R, Klebanoff MA, et al. Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol 2009;200:630.e1-8.
188. Lewis DF, Canzoneri BJ, Wang Y. Maternal circulating TNF-alpha levels are highly correlated with IL-10 levels, but not IL-6 and IL-8 levels, in women with pre-eclampsia. Am J Reprod Immunol 2009;62:269-74.
189. Vitoratos N, Economou E, Iavazzo C, et al. Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. Mediators Inflamm 2010;2010:908649.
190. Tosun M, Celik H, Avci B, et al. Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. J Matern Fetal Neonatal Med 2010;23:880-6.
191. Kalkunte S, Nevers T, Norris WE, et al. Vascular IL-10: a protective role in preeclampsia. J Reprod Immunol 2011;88:165-9.
192. Xiao JP, Yin YX, Gao YF, et al. The increased maternal serum levels of IL-6 are associated with the severity and onset of preeclampsia. Cytokine 2012;60:856-60.
193. Cemgil Arikan D, Aral M, Coskun A, et al. Plasma IL-4, IL-8, IL-12, interferon-gamma and CRP levels in pregnant women with preeclampsia, and their relation with severity of disease and fetal birth weight. J Matern Fetal Neonatal Med 2012;25:1569-73.
194. Lau SY, Guild SJ, Barrett CJ, et al. Tumor necrosis factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a systematic review and meta-analysis. Am J Reprod Immunol 2013;70:412-27.
195. Ozkan ZS, Simsek M, Ilhan F, et al. Plasma IL-17, IL-35, interferon-gamma, SOCS3 and TGF-beta levels in pregnant women with preeclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med 2014;27:1513-7.
196. Pinheiro MB, Martins-Filho OA, Mota AP, et al. Severe preeclampsia goes along with a cytokine network disturbance towards a systemic inflammatory state. Cytokine 2013;62:165-73.
197. Sahin S, Ozakpinar OB, Eroglu M, et al. The impact of platelet functions and inflammatory status on the severity of preeclampsia. J Matern Fetal Neonatal Med 2014;20:1-6.
198. Mellembakken JR, Aukrust P, Hestdal K, et al. Chemokines and leukocyte activation in the fetal circulation during preeclampsia. Hypertension 2001;38:394-8.
199. Gotsch F, Romero R, Friel L, et al. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med 2007;20:777-92.
200. Laskowska M, Laskowska K, Leszczynska-Gorzelak B, et al. Comparative analysis of the maternal and umbilical interleukin-8 levels in normal pregnancies and in pregnancies complicated by preeclampsia with intrauterine normal growth and intrauterine growth retardation. J Matern Fetal Neonatal Med 2007;20:527-32.
201. Boij R, Svensson J, Nilsson-Ekdahl K, et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 2012;68:258-70.
202. Molvarec A, Szarka A, Walentin S, et al. Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia. Reprod Biol Endocrinol 2011;9:124.
203. Du M, Basu A, Fu D, et al. Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study. Diabetes Care 2013;36:2054-61.
204. Guven MA, Coskun A, Ertas IE, et al. Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy 2009;28:190-200.
205. Stampalija T, Chaiworapongsa T, Romero R, et al. Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonatal Med 2013;26:1359-70.
206. Granne I, Southcombe JH, Snider JV, et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS One 2011;6:e24463.
207. Wang Y, Lewis DF, Gu Y, et al. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension 2011;57:336-42.
208. Sharma D, Singh A, Trivedi SS, et al. Role of endothelin and inflammatory cytokines in pre-eclampsia - a pilot North Indian study. Am J Reprod Immunol 2011;65:428-32.
209. Ozler A, Turgut A, Sak ME, et al. Serum levels of neopterin, tumor necrosis factor-alpha and Interleukin-6 in preeclampsia: relationship with disease severity. Eur Rev Med Pharmacol Sci 2012;16:1707-12.
210. Mosimann B, Wagner M, Poon LC, et al. Maternal serum cytokines at 30-33 weeks in the prediction of preeclampsia. Prenat Diagn 2013;33:823-30.
211. Zhang Z, Gao Y, Zhang L, et al. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia. Hypertens Pregnancy 2013;32:270-80.
212. Darling AM, McDonald CR, Conroy AL, et al. Angiogenic and inflammatory biomarkers in midpregnancy and small-for-gestational-age outcomes in Tanzania. Am J Obstet Gynecol 2014. [Epub ahead of print].
213. Visser S, Hermes W, Ket JC, et al. Systematic review and metaanalysis on nonclassic cardiovascular biomarkers after hypertensive pregnancy disorders. Am J Obstet Gynecol 2014. [Epub ahead of print].
214. Tjoa ML, van Vugt JM, Go AT, et al. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol 2003;59:29-37.
215. Qiu C, Luthy DA, Zhang C, et al. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am J Hypertens 2004;17:154-60.
216. Teran E, Escudero C, Calle A. C-reactive protein during normal pregnancy and preeclampsia. Int J Gynaecol Obstet 2005;89:299-300.
217. Paternoster DM, Fantinato S, Stella A, et al. C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost 2006;12:330-7.
218. Garcia RG, Celedon J, Sierra-Laguado J, et al. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens 2007;20: 98-103.
219. Ertas IE, Kahyaoglu S, Yilmaz B, et al. Association of maternal serum high sensitive C-reactive protein level with body mass index and severity of pre-eclampsia at third trimester. J Obstet Gynaecol Res 2010;36:970-7.
220. de Jonge LL, Steegers EA, Ernst GD, et al. C-reactive protein levels, blood pressure and the risks of gestational hypertensive complications: the Generation R Study. J Hypertens 2011;29:2413-21.
221. Gandevani SB, Banaem LM, Mohamadi B, et al. Association of high-sensitivity C-reactive protein serum levels in early pregnancy with the severity of preeclampsia and fetal birth weight. J Perinat Med 2012;14:1-5.
222. Kucukgoz Gulec U, Tuncay Ozgunen F, Baris Guzel A, et al. An analysis of C-reactive protein, procalcitonin, and D-dimer in pre-eclamptic patients. Am J Reprod Immunol 2012;68:331-7.
223. Chaemsaithong P, Chaiworapongsa T, Romero R, et al. Maternal plasma soluble TRAIL is decreased in preeclampsia. J Matern Fetal Neonatal Med 2014;27:217-27.
224. Rebelo F, Schlussel MM, Vaz JS, et al. C-reactive protein and later preeclampsia: systematic review and meta-analysis taking into account the weight status. J Hypertens 2013;31:16-26.
225. Chaemsaithong P, Romero R, Chaiworapongsa T, et al. Fetuin-A, a negative acute phase protein reactant, is decreased in preeclampsia. Am J Obstet Gynecol 2014. [Epub ahead of print].
226. Molvarec A, Kalabay L, Derzsy Z, et al. Preeclampsia is associated with decreased serum alpha(2)-HS glycoprotein (fetuin-A) concentration. Hypertens Res 2009;32:665-9.
227. Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, et al. Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol 2014;10:531-40.
228. Rennel E, Mellberg S, Dimberg A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007;313:1285-94.
229. Chaiworapongsa T, Romero R, Gotsch F, et al. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal Med 2010;23:167-78.
230. Gotsch F, Romero R, Espinoza J, et al. Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med 2007;20:735-44.
231. Soto E, Richani K, Romero R, et al. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy. J Matern Fetal Neonatal Med 2005;17:247-52.
232. Soto E, Romero R, Vaisbuch E, et al. Fragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis. J Matern Fetal Neonatal Med 2010;23:1085-90.
233. Chaiworapongsa T, Romero R, Whitten A, et al. Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med 2013;41: 485-504.
234. Madan I, Than NG, Romero R, et al. The peripheral whole-blood transcriptome of acute pyelonephritis in human pregnancya. J Perinat Med 2014;42:31-53.
235. Tsao PN, Chan FT, Wei SC, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med 2007;35:1955-60.
236. Shapiro NI, Yano K, Okada H, et al. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock 2008;29:452-7.
237. Kim YM, Romero R, Oh SY, et al. Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia? Am J Obstet Gynecol 2005;193: 921-7.
238. Waage A, Aasen AO. Different role of cytokine mediators in septic shock related to meningococcal disease and surgery/ polytrauma. Immunol Rev 1992;127:221-30.
239. Martin C, Boisson C, Haccoun M, et al. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. Crit Care Med 1997;25:1813-9.
240. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101-95.
241. Riche FC, Cholley BP, Panis YH, et al. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000;28:433-7.
242. Romero R, Kadar N, Vaisbuch E, et al. Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection? Am J Reprod Immunol 2010;64:113-25.
243. Mikkelsen ME, Shah CV, Scherpereel A, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012;27:522.e11-7.
244. Cunningham FG, Leveno KJ, Hankins GD, et al. Respiratory insufficiency associated with pyelonephritis during pregnancy. Obstet Gynecol 1984;63:121-5.
245. Cunningham FG, Lucas MJ. Urinary tract infections complicating pregnancy. Baillieres Clin Obstet Gynaecol 1994;8:353-73.
246. Cunningham FG, Lucas MJ, Hankins GD. Pulmonary injury complicating antepartum pyelonephritis. Am J Obstet Gynecol 1987;156:797-807.
247. Jolley JA, Wing DA. Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes. Drugs 2010;70:1643-55.
248. Jolley JA, Kim S, Wing DA. Acute pyelonephritis and associated complications during pregnancy in 2006 in US hospitals. J Matern Fetal Neonatal Med 2012;25:2494-8.
249. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol 2014;210:219.e1-6.